Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$136.97 USD

136.97
2,111,504

+0.09 (0.07%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sanofi's Toujeo Meets Key Objective in Head-to-Head Study

Sanofi's (SNY) head-to-head study comparing Toujeo long-acting insulin to Novo Nordisk's Tresiba long-acting insulin (insulin degludec) meets its objective.

    Arpita Dutt headshot

    Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes

    Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.

      Arpita Dutt headshot

      5 Biotech and Pharma Stocks with FDA Catalysts this December

      As we enter the last month of the year, here is a look at some pharma and biotech companies including Amgen (AMGN) that await a decision from the FDA for label expansions or new drugs.

        2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17

        Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.

          Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

          Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

            The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel

            The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel

              J&J Presents Positive New Data for Diabetes Drug Invokana

              Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.

                Novo Nordisk (NVO) Tops Q3 Earnings Estimates, Lags Sales

                Novo Nordisk A/S (NVO) reported third-quarter 2017 earnings of 63 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 58 cents. In fact, the reported figure was ahead of 57 cents earned a year ago.

                  Alexion (ALXN) Tops Q3 Earnings, Lags Sales, 2017 View Up

                  Alexion Pharmaceuticals, Inc.???s (ALXN) beat earnings estimates but missed sales estimates in the third quarter of 2017.

                    United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat

                    United Therapeutics' (UTHR) earnings grow year over year in the third quarter of 2017. Revenues too surpass estimates in the reported quarter.

                      Medicines Company (MDCO) Reports Q3 Loss, Revenues Miss

                      The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.

                        Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics

                        AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.

                          Impax Laboratories and Amneal Pharmaceuticals Agree to Merge

                          Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.

                            Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

                            Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

                              Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

                              Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

                                Immune Design's Sarcoma Candidate to Enter Phase III in 2018

                                Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.

                                  Bristol-Myers Gets Priority Review for Opdivo Label Expansion

                                  Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

                                    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

                                    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

                                      Why Should You Invest in Novo Nordisk (NVO) Stock Right Now

                                      Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.

                                        4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

                                        The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

                                          Johnson & Johnson Files sNDA for Label Expansion of Invokana

                                          Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.

                                            Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults

                                            Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.

                                              Orexigen's (OREX) Contrave Sales Improving on Promotions

                                              Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

                                                Arpita Dutt headshot

                                                3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day

                                                With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.

                                                  Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View

                                                  Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.